Aegle Therapeutics is a clinical stage biotech company with a platform technology focused on rare diseases. Aegle first product, AGLE-102, is a compositive of nanoparticles called extracellular vesicles (“EVs”) that are produced by stem cells. These EVs contain active biomolecules including proteins and nucleic acids which not only promote regenerative healing but are anti-inflammatory and immunomodulating as well. Aegle is currently enrolling patients in a phase 1/2a study using AGLE-102 to prevent wound progression and scarring (funded by the DOD) and will launch a phase 1/2a study in Q4 2023 for the treatment of epidermolysis bullosa. Aegle’s technology has application in a broad array of therapeutic areas including immunology (preclinical data in GvHD), dermatology and orthopedic.